These findings help explain the emergent efficacy of Tyk2 blockade in SpA spectrum–related arthritis that is not IL‐10 dependent but indicates why such strategies may not be a panacea for SpA spectrum disorder–related intestinal inflammation. The gene discussed is TYK2; the disease is arthritic joint disease.